Clinical trials: Hepatitis; Epidemic
Spontaneous Reactivation of Hepatitis B
To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B
The relevant data will be prospectively collected included patient demographics, clinical, all laboratory variables including virological tests, genotyping by direct sequencing, abdominal ultrasound, and upper gastrointestinal…
- Trial name
- NCT01732224
- Testing
- Tenofovir + Telbivudine, Tenofovir
- Where
- India
- Volunteers
- 69 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis C
Hepatitis c and Vitamin D and Iron Status
HCV is associated with vitamin D deficiency. Iron overload is frequently occurred in chronic hepatitis C patients; more than one third of HCV positive patients have elevated serum iron, ferritin, and transferrin which were linked…
- Trial name
- hepatitisc (NCT03166280)
- Testing
- Sofosbuvir 400 mg, Daclatasvir 60 mg/day
- Volunteers
- 87 people
- Sponsor
- Eman Sayed Hassan Abd Allah
Chronic Hepatitis B
Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets
This study was a single-center study, including randomized, double-blind, placebo-controlled, single-dose escalation study, multiple-dose study, food effect on pharmacokinetics and drug metabolism transformation study, drug…
- Trial name
- NCT06431438
- Testing
- TQA3810
- Where
- China
- Volunteers
- 759 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B
This multicenter, prospective, observational study will evaluate the use in clinical practice and the efficacy and safety of Pegasys (peginterferon alfa-2a) in Chinese participants with HBeAg negative chronic hepatitis B.
- Trial name
- NCT01730508
- Testing
- Pegylated Interferon Alfa (Peginterferon Alfa)
- Where
- 88 sites in China
- Volunteers
- 978 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.
- Trial name
- NCT04189276
- Testing
- ETV/TDF+T101 No.1, ETV/TDF+T101 No.2, ETV or TDF
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Chronic Hepatitis C
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
- Trial name
- NCT00724776
- Testing
- Albinterferon alfa 2b
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Novartis
Hepatitis B
Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection
The primary objective of this study is to characterize the long term (ie, 96 weeks of follow up) bone safety profile of open-label tenofovir disoproxil fumarate (tenofovir DF) treatment in CHB-infected adolescents.
- Trial name
- NCT02479880
- Testing
- Tenofovir DF, DEXA Scan
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Hepatitis C
Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, and affect on blood levels of miravirsen and telaprevir when administered together.
- Trial name
- NCT01646489
- Testing
- Miravirsen sodium, Telaprevir
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
Hepatitis C, Hepatitis C Relapse
Direct Acting Agents in Hepatitis C Patients
This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.
- Conditions
- Hepatitis C, Hepatitis C Relapse, Hepatitis C Recurrent
- Trial name
- HEPCTURKEY (NCT03145844)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,700 people
- Sponsor
- Fehmi Tabak
Hepatitis C
Qualification of Point-of-Care Assays for Management of HCV Patients
Acute or chronic HCV infection can lead to liver complications, including liver failure, cirrhosis or liver cancer. For patients with hepatitis C infection, the major clinical question remains the terms of treatment initiation.
- Trial name
- ANRS HC POC (NCT02335320)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis c
Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model
Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients.
- Trial name
- NCT03488485
- Testing
- Direct Acting Antivirals
- Where
- India
- Volunteers
- 50,000 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Depression
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
Primary end points incidence of depression defined as a Montgomery Asberg Depression Scale Score (MADRS) of 13 or higher during antiviral therapy (up to 48 weeks, depending on genotype) effect of an antidepressive pre-treatment…
- Trial name
- CIPPAD (NCT00136318)
- Testing
- Escitalopram, Peginterferon alfa-2a, Ribavirin
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Charite University, Berlin, Germany
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA…
- Trial name
- REEF-1 (NCT03982186)
- Testing
- JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analog (NA)
- Where
- 108 sites in United States, Belgium and 17 more
- Volunteers
- 471 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
Hepatitis B, Osteoporosis
Awareness of Osteoporosis in Patients With Hepatitis B Infection
Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density.
- Conditions
- Hepatitis B, Osteoporosis, Osteoporosis Risk
- Trial name
- NCT05768737
- Testing
- Patient Participation Form
- Volunteers
- 400 people
- Sponsor
- Uskudar State Hospital
Chronic Hepatitis D Infection
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
- Trial name
- LOWR-2 (NCT02430194)
- Testing
- lonafarnib, ritonavir, Pegylated interferon-alfa-2a
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis C, Chronic
Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C
Dendritic cells (DC) play a central role in the activation of T-cell responses and have shown to be very immunogenic in preclinical in vivo and in vitro assays.
- Trial name
- NCT02309086
- Testing
- Autologous dendritic cells transduced with Ad encoding NS3
- Volunteers
- 5 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Chronic Hepatitis B Infection, Chronic Hepatitis D Infection
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Primary objective: To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection Secondary objectives: 1.
- Trial name
- NCT04638439
- Testing
- P1101 + Nivolumab + Entecavir
- Where
- 5 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- PharmaEssentia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.